- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- ResMed (NYSE: RMD) hit a new 52-week high Thursday as it is currently trading at $45.52, above its previous 52-week high of $45.45 with 625,975 shares traded as of 3:42 p.m. ET. Average volume has been one million shares over the past 30 days. ResMed has a market cap of $6.44 billion and is part of the health care sector and health services industry. Shares are up 7.3% year to date as of the close of trading on Wednesday. ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The company has a P/E ratio of 24.1, above the S&P 500 P/E ratio of 17.7.